Related Experiment Videos
[Contact eczema caused by isonicotinic acid hydrazide]
Dermatosen in Beruf Und Umwelt. Occupation and Environment
|January 1, 1978
Summary
A nurse developed contact eczema from isonicotinic acid hydrazide cones used to treat an ulcerous reaction to BCG vaccination. This highlights a potential adverse reaction to tuberculostatic treatment.
Area of Science:
- Dermatology
- Pharmacology
- Infectious Disease
Background:
- Bacillus Calmette-Guérin (BCG) vaccination is a common preventative measure for tuberculosis.
- Ulcerous reactions can occur at the BCG vaccination site.
- Isonicotinic acid hydrazide (isoniazid) is a primary tuberculostatic medication used to treat tuberculosis and its complications.
Observation:
- A 20-year-old nurse presented with an ulcerous reaction following BCG vaccination.
- The patient was treated with isonicotinic acid hydrazide cones.
- Contact eczema developed within four weeks of initiating the treatment.
Findings:
- The development of contact eczema was directly linked to the topical application of isonicotinic acid hydrazide cones.
- This indicates a potential hypersensitivity or irritant reaction to the tuberculostatic agent.
- The localized nature of the rash suggests a contact dermatitis etiology.
Implications:
- Healthcare providers should be vigilant for dermatological adverse reactions to topical tuberculostatics.
- Alternative treatment strategies or formulations may be necessary for patients developing sensitivity.
- Further investigation into the safety profile of topical isonicotinic acid hydrazide in specific patient populations is warranted.